




Reducing human diseases through innovative vaccine technology.

From discovery to phase II clinical trial.



Our CDMO Services.

Discovery and production

- Vaccine strain design, modification and optimization
 - Bacterial strain construction
 - Viral strain construction and rescue
- Process development
 - Cell banking
 - Seed lot production
 - Scale-up
 - Formulation
- Pre-clinical studies
- GMP manufacturing, 1-200 liters

Characterization

- Physicochemical
 - Content
 - Higher order structure
 - Antigenicity
 - Impurities
 - Excipient
 - Stability
- Immunological
 - Innate assays
 - Humoral assays
 - Cellular assays


Stellar track record

- 2 OMV vaccines out-licensed
- 1 conjugate AMR vaccine out-licensed and marketed
- 1 cell-based viral vaccine out-licensed and marketed
- 300+ scientific publications
- 50+ customers worldwide
- 10+ partnerships

Our proprietary vaccine development platforms.



OMV-Vacc Technology
Outer Membrane Vesicles
 Highly versatile platform with a wide range of applications for prophylactic and therapeutic vaccines



Cell-Vacc Technology
Vero and HEK293 cells
 Globally used for routine, large-scale commercial vaccine manufacturing



Con-Vacc Technology
Conjugation
 20-year track record in designing, developing and characterizing conjugate vaccines



E.CO-Vacc Technology
E.coli expression
 Versatile protein expression platform for oncology, infectious diseases and other applications



Our unique pipeline of vaccine candidates, open for licensing.

	Vaccine	Target	Technology	Development	Pre-clinical	Clinical phase I	Clinical phase II
Out-licensed / marketed*	Avacc 17®	Hib	Con-Vacc	[Progress bar]			
	Avacc 29®	Polio	Cell-Vacc	[Progress bar]			
	Avacc 3®	Pertussis	OMV-Vacc	[Progress bar]			
	Avacc 13®	MenB	OMV-Vacc	[Progress bar]			
Open for licensing	Avacc 10®	COVID-19	OMV-Vacc	[Progress bar]			
	Avacc 11®	Gonorrhea	OMV-Vacc	[Progress bar]			
	Avacc 5®	EVD68	Cell-Vacc	[Progress bar]			
	Avacc 31®	ALS	Con-Vacc	[Progress bar]			
	Avacc 2®	HFMD	Cell-Vacc	[Progress bar]			
	Avacc 7®	Lyme	OMV-Vacc	[Progress bar]			

* Open for licensing in certain regions

Avacc 2® HFMD

- First-in-class quadrivalent vaccine
- Induces high antibody titers
- GMP seed lots produced for 3 strains

Avacc 3® Pertussis

- Broad protection
- Good safety profile
- Out-licensed for further development

Avacc 5® EVD68

- Induces high virus neutralizing titers
- GMP seed lot produced
- Pre-clinical studies in 2024

Avacc 7® Lyme

- Borrelial antigens expressed on OMV
- Induces a strong antibody response
- Clearance in mouse challenge model

Avacc 10® COVID-19

- Intranasal vaccine
- Excellent pre-clinical data
- Phase I clinical trial in progress

Avacc 11® Gonorrhea

- First-in-class intranasal vaccine
- Effective in animal models
- Co-developed with Therapyx Inc.

Avacc 13® MenB

- Nona-valent PorA vaccine
- Excellent pre-clinical data
- Out-licensed for further development

Avacc 17® Hib

- Cost-effective and efficacious
- Licensed in China and marketed in India
- Other regions available for partnering

Avacc 31® ALS

- Conjugate vaccine
- Prophylactic and therapeutic
- Co-developed with German Center for Neurodegenerative Diseases (DZNE)

Learn more

Are you interested in our CDMO services, vaccine development platforms or pipeline of vaccine candidates? Our Business Development Team is happy to discuss all possibilities with you.

Get in touch!

email us at: bd@intravacc.nl

Disclaimer: Intravacc assumes no liability or responsibility for any errors or omissions in the information included in this Vaccsheet, including forward looking statements. The information is provided "as is" with no guarantees of completeness, accuracy or timeliness, and without warranties of any kind, expressed or implied.

itvvcorp.0723